

ISSUE @ A GLANCE



COVID-19: (mis)managing an announced Black Swan
T.F. Lüscher

1779

CardioPulse

COVID-19 experience in Bergamo, Italy
M. Senni

1783

Priorities for Cath labs in the COVID-19 tsunami
G. Campo, C. Rapezzi, L. Tavazzi, and R. Ferrari

1784

Donning and doffing of personal protective equipment (PPE) for angiography during the COVID-19 crisis
T.-J. John, K. Hassan, and H. Weich

1786

Experiences and lesson strategies for cardiology from the COVID-19 outbreak in Wuhan, China, by 'on the scene' cardiologists
L. Zhang, Y. Fan, and Z. Lu

1788

Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak
Z.-C. Jing, H.-D. Zhu, X.-W. Yan, W.-Z. Chai, and S. Zhang; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital

1791

CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic
M. Linschoten and F.W. Asselbergs; on behalf of CAPACITY-COVID collaborative consortium

1795

Call to action for the cardiovascular side of COVID-19
C. Emanueli, L. Badimon, F. Martelli, I. Potočnjak, I. Carpusca, E.L. Robinson, Y. Devaux on behalf of the EU-CardioRNA COST Action (CA17129)

1796


VIEWPOINTS

Prevention and epidemiology

Coronaviruses and the cardiovascular system: acute and long-term implications
T.-Y. Xiong, S. Redwood, B. Prendergast, and M. Chen

1798

B



Pathophysiology

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?
G.M. Kuster, O. Pfister, T. Burkard, Q. Zhou, R. Twerenbold, P. Haaf, A.F. Widmer, and S. Osswald

1801

EHJ BRIEF COMMUNICATION

Myocardial disease

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts
L. Nicin, W.T. Abplanalp, H. Mellentin, B. Kattih, L. Tombor, D. John, J.D. Schmitto, J. Heineke, F. Emrich, M. Arsalan, T. Holubec, T. Walther, A.M. Zeiher, and S. Dimmeler

1804

Editorial

SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?
T. Thum

1807


FAST TRACK CLINICAL RESEARCH

Heart failure/cardiomyopathy

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

I.E. Sama, A. Ravera, B.T. Santema, H. van Goor, J.M. ter Maaten, J.G.F. Cleland, M. Rienstra, A.W. Friedrich, N.J. Samani, L.L. Ng, K. Dickstein, C.C. Lang, G. Filippatos, S.D. Anker, P. Ponikowski, M. Metra, D.J. van Veldhuisen, and A.A. Voors

1810



Editorial

Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19

G.Y. Oudit and M.A. Pfeffer

1818

Prevention and epidemiology

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

R.M. Inciardi, M. Adamo, L. Lupi, D.S. Cani, M. Di Pasquale, D. Tomasoni, L. Italia, G. Zacccone, C. Tedino, D. Fabbriatore, A. Curnis, P. Faggiano, E. Gorga, C.M. Lombardi, G. Milesi, E. Vizzardi, M. Volpini, S. Nodari, C. Specchia, R. Maroldi, M. Bezzi, and M. Metra

1821

Editorial

At the heart of COVID-19

P. Pellicori

1830

CLINICAL REVIEW

Disease management

Deleterious effects of viral pneumonia on cardiovascular system

J. Duan, Y. Wu, C. Liu, C. Yang, and L. Yang

1833

CURRENT OPINION

Interventional cardiology

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic

A. Chieffo, G.G. Stefanini, S. Price, E. Barbato, G. Tarantini, N. Karam, R. Moreno, G.L. Buchanan, M. Gilard, S. Halvorsen, K. Huber, S. James, F.-J. Neumann, H. Möllmann, M. Roffi, G. Tavazzi, J. Mauri Ferré, S. Windecker, D. Dudek, and A. Baumbach

1839

DISCUSSION FORUM

Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage

B. Metzler, P. Siostrzonek, R.K. Binder, A. Bauer, and S.J. Reinstadler

1852

Is fulminant myocarditis caused by circulating human coronaviruses?

R.K. Dare

1854

Immune-mediated mechanism in coronavirus fulminant myocarditis

X. Wei, Y. Fang, and H. Hu

1855

Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19

M.M. Ciulla

1856

Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence

G.M. Kuster and S. Osswald; on behalf of the authors

1857

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

G.B. Danzi, M. Loffi, G. Galeazzi, and E. Gherbesi

1858

COVID-19-related myocarditis in a 21-year-old female patient

In-Cheol Kim, J.Y. Kim, H.A. Kim, and S. Han

1859

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

P. Meyer, S. Degrauwe, C.V. Delden, J.-R. Ghadri, and C. Templin

1860


Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

S. Sala, G. Peretto, M. Gramegna, A. Palmisano, A. Villatore, D. Vignale, F. De Cobelli, M. Tresoldi, A.M. Cappelletti, C. Basso, C. Godino, and A. Esposito

1861

 Open Access Paper

 For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org